Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2483519 | 1.00 | FPR2 (0.49) | FPR2POLBCYP2D6SRCLMNA | |
| SCHEMBL2483521 | 1.00 | FPR2 (0.49) | FPR2POLBCYP2D6SRCLMNA | |
| SCHEMBL28534876 | 0.98 | FPR2 (0.47) | FPR2POLBCYP2D6SRCLMNA | |
| SCHEMBL11301777 | 0.96 | CA12 (0.45) | FPR2POLBCYP2D6SRCLMNA | |
| Ethylene Glycol SCHEMBL27658801 | 0.92 | FPR2 (0.44) | FPR2POLBCYP2D6SRCLMNA | |
| SCHEMBL7573687 | 0.88 | MAOA (0.48) | FPR2CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL7583413 | 0.87 | FPR2 (0.67) | FPR2LMNACA12ALDH1A1MAPT | |
| SCHEMBL1696047 | 0.87 | MDM2 (0.48) | FPR2LMNACA12CA9KDM4E | |
| SCHEMBL9298520 | 0.87 | CNR1 (0.53) | LMNACA12CA9ALDH1A1MAPT | |
| SCHEMBL2483340 | 0.87 | NPC1 (0.47) | FPR2POLBCYP2D6LMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-55011126-A | — | — | None | — | — | JP | disclosed |
| US-9040566-B2 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120058983-A1 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | US | disclosed |
| US-8101601-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-24 | — | — | US | disclosed |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | BAYER HELTHCARE AG | 2011-02-10 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-5374656-A | Nervous system disorders, gastrointestinal disorders | RHONE-POULENC RORER, S.A. (FR) | 1994-12-20 | — | — | US | disclosed |
| US-5223529-A | Nervous system and gastrointestinal disorders | RHONE-POULENC SANTE (FR) | 1993-06-29 | — | — | US | disclosed |
| US-4248677-A | ELECTROCHEMICAL REDUCTION OF IMINES | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1981-02-03 | — | — | US | disclosed |
| JP-S5511126-A | PRODUCTION OF N-SUBSTITUTED PHENYL GLYCINE | TOKUYAMA SODA CO LTD | 1980-01-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | PLG, AADAC, DNPEP | FPR2 950/4885POLB 2762/4885CYP2D6 428/4885 |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | AADAC, AADAT, AASDHPPT | FPR2 1416/4885POLB 3122/4885CYP2D6 182/4885 |
| US-20100273789-A1 | AMINOACYL PRODRUGS | AADAC, DNPEP, AADAT | FPR2 657/4885POLB 3372/4885CYP2D6 104/4885 |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | PLG, AADAC, DNPEP | FPR2 950/4885POLB 2762/4885CYP2D6 428/4885 |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | DNPEP, AADAT, DAO | FPR2 2791/4885POLB 4016/4885CYP2D6 128/4885 |
| US-20120058983-A1 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | ADORA1, ADORA3, ADORA2A | FPR2 4043/4885POLB 2245/4885CYP2D6 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.